RU2010141742A - С2оrf18 В КАЧЕСТВЕ ГЕНА-МИШЕНИ ДЛЯ ТЕРАПИИ И ДИАГНОСТИКИ РАКА - Google Patents
С2оrf18 В КАЧЕСТВЕ ГЕНА-МИШЕНИ ДЛЯ ТЕРАПИИ И ДИАГНОСТИКИ РАКА Download PDFInfo
- Publication number
- RU2010141742A RU2010141742A RU2010141742/10A RU2010141742A RU2010141742A RU 2010141742 A RU2010141742 A RU 2010141742A RU 2010141742/10 A RU2010141742/10 A RU 2010141742/10A RU 2010141742 A RU2010141742 A RU 2010141742A RU 2010141742 A RU2010141742 A RU 2010141742A
- Authority
- RU
- Russia
- Prior art keywords
- c2orf18
- polypeptide
- seq
- cancer
- level
- Prior art date
Links
- 101000637757 Homo sapiens Solute carrier family 35 member F6 Proteins 0.000 title claims abstract 46
- 102100032109 Solute carrier family 35 member F6 Human genes 0.000 title claims abstract 40
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 18
- 201000011510 cancer Diseases 0.000 title claims abstract 18
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 10
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 36
- 229920001184 polypeptide Polymers 0.000 claims abstract 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract 22
- 238000012360 testing method Methods 0.000 claims abstract 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 17
- 230000027455 binding Effects 0.000 claims abstract 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 6
- 230000004071 biological effect Effects 0.000 claims abstract 6
- 239000012472 biological sample Substances 0.000 claims abstract 6
- 230000005907 cancer growth Effects 0.000 claims abstract 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 5
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 5
- 238000012216 screening Methods 0.000 claims abstract 5
- 230000002265 prevention Effects 0.000 claims abstract 3
- 239000000556 agonist Substances 0.000 claims abstract 2
- 239000005557 antagonist Substances 0.000 claims abstract 2
- 238000001574 biopsy Methods 0.000 claims abstract 2
- 238000011161 development Methods 0.000 claims abstract 2
- 238000009396 hybridization Methods 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims abstract 2
- 108020004999 messenger RNA Proteins 0.000 claims abstract 2
- 239000000523 sample Substances 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims 28
- 125000003729 nucleotide group Chemical group 0.000 claims 28
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 5
- 102100026396 ADP/ATP translocase 2 Human genes 0.000 claims 4
- 101000718417 Homo sapiens ADP/ATP translocase 2 Proteins 0.000 claims 4
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 108091027568 Single-stranded nucleotide Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000037425 regulation of transcription Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3603508P | 2008-03-12 | 2008-03-12 | |
| US61/036,035 | 2008-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010141742A true RU2010141742A (ru) | 2012-04-20 |
Family
ID=41064968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141742/10A RU2010141742A (ru) | 2008-03-12 | 2009-03-10 | С2оrf18 В КАЧЕСТВЕ ГЕНА-МИШЕНИ ДЛЯ ТЕРАПИИ И ДИАГНОСТИКИ РАКА |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110098339A1 (enExample) |
| EP (1) | EP2262541A4 (enExample) |
| JP (1) | JP2011518541A (enExample) |
| KR (1) | KR20100128326A (enExample) |
| CN (1) | CN102026672A (enExample) |
| BR (1) | BRPI0909310A2 (enExample) |
| CA (1) | CA2718382A1 (enExample) |
| RU (1) | RU2010141742A (enExample) |
| WO (1) | WO2009113295A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101406314B1 (ko) * | 2011-07-19 | 2014-06-12 | 연세대학교 산학협력단 | 췌장암 암 줄기세포 특성에 기초한 췌장암의 치료용 타겟 |
| CN116794325B (zh) * | 2023-06-15 | 2024-05-10 | 中山大学 | 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110593A2 (en) * | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| KR20070101610A (ko) * | 2006-04-11 | 2007-10-17 | 주식회사 바이오인프라 | Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법 |
-
2009
- 2009-03-10 JP JP2010536258A patent/JP2011518541A/ja active Pending
- 2009-03-10 KR KR1020107022812A patent/KR20100128326A/ko not_active Withdrawn
- 2009-03-10 RU RU2010141742/10A patent/RU2010141742A/ru not_active Application Discontinuation
- 2009-03-10 CA CA2718382A patent/CA2718382A1/en not_active Abandoned
- 2009-03-10 WO PCT/JP2009/001057 patent/WO2009113295A1/en not_active Ceased
- 2009-03-10 EP EP09718793A patent/EP2262541A4/en not_active Withdrawn
- 2009-03-10 CN CN2009801171940A patent/CN102026672A/zh active Pending
- 2009-03-10 US US12/921,766 patent/US20110098339A1/en not_active Abandoned
- 2009-03-10 BR BRPI0909310A patent/BRPI0909310A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011518541A (ja) | 2011-06-30 |
| BRPI0909310A2 (pt) | 2017-06-27 |
| WO2009113295A1 (en) | 2009-09-17 |
| CA2718382A1 (en) | 2009-09-17 |
| EP2262541A1 (en) | 2010-12-22 |
| CN102026672A (zh) | 2011-04-20 |
| KR20100128326A (ko) | 2010-12-07 |
| US20110098339A1 (en) | 2011-04-28 |
| EP2262541A4 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018229487B2 (en) | Treatment of fibrosis | |
| KR102240323B1 (ko) | 유방암 전이의 진단, 예후 및 치료 방법 | |
| JP2012135301A5 (enExample) | ||
| JP2009502115A5 (enExample) | ||
| JP2008532477A5 (enExample) | ||
| JP2012501164A5 (enExample) | ||
| US6974672B2 (en) | Gene amplification in cancer | |
| WO2007093042A1 (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling | |
| RU2010111135A (ru) | Связанные со злокачественными опухолями гены cdca5. epha7. stk31 и wdhd1 | |
| US20040005615A1 (en) | Amplification and overexpression of oncogenes | |
| JP2005511023A5 (enExample) | ||
| JP2009505633A5 (enExample) | ||
| US20240247264A1 (en) | NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS | |
| WO2020175898A1 (ko) | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| JPWO2017195809A1 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| RU2010141742A (ru) | С2оrf18 В КАЧЕСТВЕ ГЕНА-МИШЕНИ ДЛЯ ТЕРАПИИ И ДИАГНОСТИКИ РАКА | |
| US20050059011A1 (en) | Amplification and overexpression of oncogenes | |
| US20050026194A1 (en) | Gene amplification and overexpression in cancer | |
| US20220145395A1 (en) | Transpochimeric Gene Transcripts (TCGTS) As Cancer Biomarkers | |
| AU2017285726A1 (en) | Methods for diagnosing and treating metastatic cancer | |
| RU2011111551A (ru) | C12orf48 как ген-мишень для лечения и диагностики рака | |
| WO2008042510A2 (en) | Genes and gene products differentially expressed during heart failure | |
| US20050112678A1 (en) | Gene amplification and overexpression in cancer | |
| JP2014523736A5 (enExample) | ||
| JP2011518541A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20120313 |